Xenon Pharmaceuticals (XENE) FDA Approvals $54.12 -0.56 (-1.02%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$54.15 +0.03 (+0.06%) As of 05/21/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Xenon Pharmaceuticals' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Xenon Pharmaceuticals (XENE). Over the past two years, Xenon Pharmaceuticals has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as azetukalner. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Azetukalner FDA Regulatory Timeline and Events Azetukalner is a drug developed by Xenon Pharmaceuticals for the following indication: in patients with focal onset seizures. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Positive Data - April 19,2026Positive Data Phase 3Drug: azetukalnerAnnounced Date: April 19, 2026Indication: in patients with focal onset seizures AnnouncementXenon Pharmaceuticals Inc presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois.AI SummaryXenon Pharmaceuticals presented positive Phase 3 X-TOLE2 data at the American Academy of Neurology Annual Meeting (April 18–22, 2026, Chicago) showing that azetukalner (AZK), a novel, potent KV7 channel opener, was effective and well tolerated in adults with focal onset seizures. The results were highlighted in a late‑breaking oral and poster session (Oral & Poster Presentation #7, LS1), where investigators reported clinically meaningful reductions in seizure frequency along with a favorable safety and tolerability profile. The X-TOLE2 findings support AZK’s potential as a new treatment option for people with focal epilepsy. Xenon emphasized these efficacy and safety outcomes to clinicians and researchers at AAN and noted that additional data from ongoing studies will help define long‑term effects and real‑world use. The results could inform future clinical practice and continued development of AZK for focal onset seizures.Read AnnouncementPresentation - April 7,2026Presentation Drug: azetukalnerAnnounced Date: April 7, 2026Indication: in patients with focal onset seizures AnnouncementXenon Pharmaceuticals Inc announced multiple presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Five abstracts will be presented, including a Late-breaking Science oral and poster presentation of the topline Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures (FOS), as well as a poster presentation of long-term 48-month azetukalner data from the X-TOLE open label extension study.AI SummaryXenon Pharmaceuticals announced it will present multiple abstracts at the American Academy of Neurology (AAN) Annual Meeting, April 18–22, 2026 in Chicago. The company will deliver five presentations, highlighted by a Late‑breaking Science oral and poster session revealing topline Phase 3 X‑TOLE2 results for azetukalner in focal onset seizures (FOS). This late‑breaking slot underscores the importance of the Phase 3 findings to the epilepsy field. In addition, Xenon will present long‑term data from the X‑TOLE open‑label extension, including a poster with 48‑month azetukalner safety and durability results. Other planned abstracts cover efficacy and safety in FOS, real‑world epilepsy outcomes, and early‑stage epilepsy research, offering clinicians and researchers a broad view of azetukalner’s clinical profile and longer‑term performance.Read AnnouncementPositive Results - March 9,2026Positive Results Phase 3Drug: azetukalnerAnnounced Date: March 9, 2026Indication: in patients with focal onset seizures AnnouncementXenon Pharmaceuticals Inc announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS). Azetukalner is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.AI SummaryXenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner, a novel KV7 potassium channel opener for focal onset seizures (FOS). The trial met its primary endpoint in both dose groups. The 25 mg dose produced a 53.2% median reduction in monthly FOS frequency from baseline versus a 10.4% reduction for placebo (p=6×10⁻¹²). Key secondary results showed Responder Rate 50 (≥50% seizure reduction) of 54.8% for 25 mg and 37.6% for 15 mg, versus 20.8% for placebo (p=8×10⁻⁸ and p=0.003, respectively). X-TOLE2 outperformed the Phase 2b X-TOLE study, with a placebo-adjusted median percent change of −42.7% (25 mg) versus −34.6% previously. Azetukalner was generally well tolerated, with a safety profile consistent with earlier data. Xenon plans to submit a New Drug Application for azetukalner in FOS in Q3 2026. X-TOLE2 results will be presented as a Late Breaking Science oral presentation at AAN on April 19, and the company is hosting a conference call and webcast today at 8:00 am ET.Read AnnouncementTop-line data - March 7,2026Top-Line Data Phase 3Drug: azetukalnerAnnounced Date: March 7, 2026Indication: in patients with focal onset seizures AnnouncementXenon Pharmaceuticals Inc will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026.AI SummaryXenon Pharmaceuticals announced topline Phase 3 X-TOLE2 results for azetukalner on Monday, March 9, 2026. Azetukalner is a novel, potent KV7 potassium channel opener being developed for focal onset seizures (FOS). The study met its primary endpoint in both dose groups: the 25 mg dose produced a −53.2% median percent change (MPC) in monthly FOS frequency versus −10.4% for placebo (p=0.000000000006). X-TOLE2 outperformed the prior Phase 2b X-TOLE, with a placebo‑adjusted MPC of −42.7% for the 25 mg group versus −34.6% previously. The trial also met a key secondary endpoint: responder rates (≥50% reduction) were 54.8% for 25 mg and 37.6% for 15 mg, compared with 20.8% for placebo (p=0.00000008 and p=0.003). Azetukalner was generally well tolerated with a safety profile consistent with earlier data. Xenon expects to submit a New Drug Application in Q3 2026, will feature the data as a Late Breaking Science presentation at AAN in April, and hosted a conference call and webcast the same day.Read Announcement Xenon Pharmaceuticals FDA Events - Frequently Asked Questions Has Xenon Pharmaceuticals received FDA approval? As of now, Xenon Pharmaceuticals (XENE) has not received any FDA approvals for its therapy in the last two years. What drugs has Xenon Pharmaceuticals submitted to the FDA? In the past two years, Xenon Pharmaceuticals (XENE) has reported FDA regulatory activity for azetukalner. What is the most recent FDA event for Xenon Pharmaceuticals? The most recent FDA-related event for Xenon Pharmaceuticals occurred on April 19, 2026, involving azetukalner. The update was categorized as "Positive Data," with the company reporting: "Xenon Pharmaceuticals Inc presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois." What conditions do Xenon Pharmaceuticals' current drugs treat? Currently, Xenon Pharmaceuticals has one therapy (azetukalner) targeting the following condition: in patients with focal onset seizures. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Adagio Medical FDA EventsBioCardia FDA EventsCognition Therapeutics FDA EventsCorbus Pharmaceuticals FDA EventsPrecision BioSciences FDA EventsHUTCHMED FDA EventsEli Lilly and Company FDA EventsTeleflex FDA EventsBioMarin Pharmaceutical FDA EventsDiaMedica Therapeutics FDA EventsDyne Therapeutics FDA EventsGuardant Health FDA EventsLigand Pharmaceuticals FDA EventsMadrigal Pharmaceuticals FDA EventsMetaVia FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Roivant Sciences FDA Events Moderna FDA Events Viatris FDA Events Genmab A/S FDA Events Ascendis Pharma A/S FDA Events Summit Therapeutics FDA Events BridgeBio Pharma FDA Events Axsome Therapeutics FDA Events Dr. Reddy's Laboratories FDA Events Arrowhead Pharmaceuticals FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:XENE last updated on 4/20/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Positive Data - April 19,2026Positive Data Phase 3Drug: azetukalnerAnnounced Date: April 19, 2026Indication: in patients with focal onset seizures AnnouncementXenon Pharmaceuticals Inc presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois.AI SummaryXenon Pharmaceuticals presented positive Phase 3 X-TOLE2 data at the American Academy of Neurology Annual Meeting (April 18–22, 2026, Chicago) showing that azetukalner (AZK), a novel, potent KV7 channel opener, was effective and well tolerated in adults with focal onset seizures. The results were highlighted in a late‑breaking oral and poster session (Oral & Poster Presentation #7, LS1), where investigators reported clinically meaningful reductions in seizure frequency along with a favorable safety and tolerability profile. The X-TOLE2 findings support AZK’s potential as a new treatment option for people with focal epilepsy. Xenon emphasized these efficacy and safety outcomes to clinicians and researchers at AAN and noted that additional data from ongoing studies will help define long‑term effects and real‑world use. The results could inform future clinical practice and continued development of AZK for focal onset seizures.Read Announcement
Presentation - April 7,2026Presentation Drug: azetukalnerAnnounced Date: April 7, 2026Indication: in patients with focal onset seizures AnnouncementXenon Pharmaceuticals Inc announced multiple presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Five abstracts will be presented, including a Late-breaking Science oral and poster presentation of the topline Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures (FOS), as well as a poster presentation of long-term 48-month azetukalner data from the X-TOLE open label extension study.AI SummaryXenon Pharmaceuticals announced it will present multiple abstracts at the American Academy of Neurology (AAN) Annual Meeting, April 18–22, 2026 in Chicago. The company will deliver five presentations, highlighted by a Late‑breaking Science oral and poster session revealing topline Phase 3 X‑TOLE2 results for azetukalner in focal onset seizures (FOS). This late‑breaking slot underscores the importance of the Phase 3 findings to the epilepsy field. In addition, Xenon will present long‑term data from the X‑TOLE open‑label extension, including a poster with 48‑month azetukalner safety and durability results. Other planned abstracts cover efficacy and safety in FOS, real‑world epilepsy outcomes, and early‑stage epilepsy research, offering clinicians and researchers a broad view of azetukalner’s clinical profile and longer‑term performance.Read Announcement
Positive Results - March 9,2026Positive Results Phase 3Drug: azetukalnerAnnounced Date: March 9, 2026Indication: in patients with focal onset seizures AnnouncementXenon Pharmaceuticals Inc announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS). Azetukalner is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.AI SummaryXenon Pharmaceuticals announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner, a novel KV7 potassium channel opener for focal onset seizures (FOS). The trial met its primary endpoint in both dose groups. The 25 mg dose produced a 53.2% median reduction in monthly FOS frequency from baseline versus a 10.4% reduction for placebo (p=6×10⁻¹²). Key secondary results showed Responder Rate 50 (≥50% seizure reduction) of 54.8% for 25 mg and 37.6% for 15 mg, versus 20.8% for placebo (p=8×10⁻⁸ and p=0.003, respectively). X-TOLE2 outperformed the Phase 2b X-TOLE study, with a placebo-adjusted median percent change of −42.7% (25 mg) versus −34.6% previously. Azetukalner was generally well tolerated, with a safety profile consistent with earlier data. Xenon plans to submit a New Drug Application for azetukalner in FOS in Q3 2026. X-TOLE2 results will be presented as a Late Breaking Science oral presentation at AAN on April 19, and the company is hosting a conference call and webcast today at 8:00 am ET.Read Announcement
Top-line data - March 7,2026Top-Line Data Phase 3Drug: azetukalnerAnnounced Date: March 7, 2026Indication: in patients with focal onset seizures AnnouncementXenon Pharmaceuticals Inc will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026.AI SummaryXenon Pharmaceuticals announced topline Phase 3 X-TOLE2 results for azetukalner on Monday, March 9, 2026. Azetukalner is a novel, potent KV7 potassium channel opener being developed for focal onset seizures (FOS). The study met its primary endpoint in both dose groups: the 25 mg dose produced a −53.2% median percent change (MPC) in monthly FOS frequency versus −10.4% for placebo (p=0.000000000006). X-TOLE2 outperformed the prior Phase 2b X-TOLE, with a placebo‑adjusted MPC of −42.7% for the 25 mg group versus −34.6% previously. The trial also met a key secondary endpoint: responder rates (≥50% reduction) were 54.8% for 25 mg and 37.6% for 15 mg, compared with 20.8% for placebo (p=0.00000008 and p=0.003). Azetukalner was generally well tolerated with a safety profile consistent with earlier data. Xenon expects to submit a New Drug Application in Q3 2026, will feature the data as a Late Breaking Science presentation at AAN in April, and hosted a conference call and webcast the same day.Read Announcement
